Core-shell-type lipid-polymer hybrid nanoparticles as a drug delivery platform

Bivash Mandal, Himanshu Bhattacharjee, Nivesh Mittal, Hongkee Sah, Pavan Balabathula, Laura A. Thoma, George C. Wood

Research output: Contribution to journalReview articlepeer-review

301 Scopus citations

Abstract

The focus of nanoparticle design over the years has evolved toward more complex nanoscopic core-shell architecture using a single delivery system to combine multiple functionalities within nanoparticles. Core-shell-type lipid-polymer hybrid nanoparticles (CSLPHNs), which combine the mechanical advantages of biodegradable polymeric nanoparticles and biomimetic advantages of liposomes, have emerged as a robust and promising delivery platform. In CSLPHNs, a biodegradable polymeric core is surrounded by a shell composed of layer(s) of phospholipids. The hybrid architecture can provide advantages such as controllable particle size, surface functionality, high drug loading, entrapment of multiple therapeutic agents, tunable drug release profile, and good serum stability. This review focuses on current research trends on CSLPHNs including classification, advantages, methods of preparation, physicochemical characteristics, surface modifications, and immunocompatibility. Additionally, the review deals with applications for cancer chemotherapy, vaccines, and gene therapeutics. From the Clinical Editor: This comprehensive review covers the current applications of core-shell-type lipid-polymer hybrid nanoparticles, which combine the mechanical advantages of biodegradable polymeric nanoparticles and biomimetic advantages of liposomes to enable an efficient drug delivery system.

Original languageEnglish
Pages (from-to)474-491
Number of pages18
JournalNanomedicine: Nanotechnology, Biology, and Medicine
Volume9
Issue number4
DOIs
StatePublished - May 2013

Keywords

  • Cancer
  • Core-shell
  • Drug delivery
  • Lipid-polymer hybrid nanoparticles
  • Lipoparticles

Fingerprint

Dive into the research topics of 'Core-shell-type lipid-polymer hybrid nanoparticles as a drug delivery platform'. Together they form a unique fingerprint.

Cite this